Hynes, Matthew C.
Nguyen, Paul
Groome, Patti A.
Asai, Yuka
Mavor, Meaghan E.
Baetz, Tara D.
Hanna, Timothy P.
Funding for this research was provided by:
Ontario Institute for Cancer Research (#IA-035)
Canadian Institutes of Health Research (MOP 137022)
Article History
Received: 1 March 2022
Accepted: 15 June 2022
First Online: 1 July 2022
Declarations
:
: This study was performed in accordance with institutional ethical guidelines and the declaration of Helsinki. A waiver of informed consent was granted based on the Personal Health Information Protection Act, Sect. 44(1), with ethics approval by the Queen’s University Health Sciences and Affiliated Teaching Hospitals Research Ethics Board (EPID-425–13).
: Not applicable.
: TDB reports unrelated advisory board/honorarium for Astra Zeneca, Abbvie, Gilead, Roche, Novartis, Merck, and Bristol Myers Squibb. YA reports unrelated research grants from the Canadian Dermatology Foundation, Sanofi, Pfizer, Leo Pharma, and Novartis and honoraria from the Canadian Society for Allergy and Immunology, Medexus, Janssen, Eli Lilly, Pfizer, UCB, L’Oreal, Aralez, Bausch and Novartis. The remaining authors have no declarations of competing interest.